ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.290,66
0,31%
S&P 500
5.475,09
0,27%
Dow Jones
39.169,52
0,13%
Euro vs US Dollar
1,07322
-0,04%
Bitcoin
63.175,66
0,52%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Lixte Biotechnology Holdings Inc (LIXTW)

  7. Lixte Biotechnology Holdings Inc (LIXTW) News

LIXTW

Lixte Biotechnology (LIXTW)

Lixte Biotechnology Holdings Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:LIXTW
DatumZeitQuelleÜberschriftSymbolFirma
14/06/202420h47Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTWLixte Biotechnology Holdings Inc
14/06/202417h00GlobeNewswire Inc.LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical TrialNASDAQ:LIXTWLixte Biotechnology Holdings Inc
14/06/202415h30GlobeNewswire Inc.LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical TrialNASDAQ:LIXTWLixte Biotechnology Holdings Inc
14/06/202414h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTWLixte Biotechnology Holdings Inc
06/06/202414h30GlobeNewswire Inc.Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune SystemNASDAQ:LIXTWLixte Biotechnology Holdings Inc
05/06/202421h55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTWLixte Biotechnology Holdings Inc
03/06/202414h30GlobeNewswire Inc.LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical OfficerNASDAQ:LIXTWLixte Biotechnology Holdings Inc
29/05/202423h29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTWLixte Biotechnology Holdings Inc
20/05/202423h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTWLixte Biotechnology Holdings Inc
09/05/202418h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTWLixte Biotechnology Holdings Inc
09/05/202414h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LIXTWLixte Biotechnology Holdings Inc
08/05/202415h25GlobeNewswire Inc.LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”NASDAQ:LIXTWLixte Biotechnology Holdings Inc
24/04/202421h25AllPennyStocks.comMixed Shelf Filing Gives Micro Cap Delayed BoostNASDAQ:LIXTWLixte Biotechnology Holdings Inc
27/03/202420h35AllPennyStocks.comBiotech Steals The Show Following Pre-Clinical Data AnnouncementNASDAQ:LIXTWLixte Biotechnology Holdings Inc
27/03/202413h30GlobeNewswire Inc.NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIESNASDAQ:LIXTWLixte Biotechnology Holdings Inc
21/03/202413h30GlobeNewswire Inc.LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer TreatmentsNASDAQ:LIXTWLixte Biotechnology Holdings Inc
27/02/202414h30GlobeNewswire Inc.Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer ResearchNASDAQ:LIXTWLixte Biotechnology Holdings Inc
26/02/202414h30GlobeNewswire Inc.LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCINASDAQ:LIXTWLixte Biotechnology Holdings Inc
29/01/202414h30GlobeNewswire Inc.First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma TrialNASDAQ:LIXTWLixte Biotechnology Holdings Inc
13/11/202314h30GlobeNewswire Inc.LIXTE Biotechnology Provides Update on Clinical Progress and Expanding CollaborationsNASDAQ:LIXTWLixte Biotechnology Holdings Inc
16/10/202314h30GlobeNewswire Inc.LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand CollaborationNASDAQ:LIXTWLixte Biotechnology Holdings Inc
09/10/202314h30GlobeNewswire Inc.LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. KovachNASDAQ:LIXTWLixte Biotechnology Holdings Inc
26/09/202314h30GlobeNewswire Inc.LIXTE Appoints Bas van der Baan as President and Chief Executive OfficerNASDAQ:LIXTWLixte Biotechnology Holdings Inc
20/09/202314h30GlobeNewswire Inc.LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian CancerNASDAQ:LIXTWLixte Biotechnology Holdings Inc
20/07/202322h05GlobeNewswire Inc.LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq RulesNASDAQ:LIXTWLixte Biotechnology Holdings Inc
18/07/202314h00GlobeNewswire Inc.LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq RulesNASDAQ:LIXTWLixte Biotechnology Holdings Inc
17/07/202314h30GlobeNewswire Inc.Preclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and ChemotherapyNASDAQ:LIXTWLixte Biotechnology Holdings Inc
01/12/202018h30GlobeNewswire Inc.Lixte Biotechnology Holdings, Inc. Announces Closing of Public Offering and Uplisting to NasdaqNASDAQ:LIXTWLixte Biotechnology Holdings Inc
30/11/202021h52Business WireWestPark Capital Announces Closing of $5,700,000 Follow-On Offering & NASDAQ Up-listing of Lixte Biotechnology Holdings, Inc....NASDAQ:LIXTWLixte Biotechnology Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:LIXTW

Kürzlich von Ihnen besucht

USOTC
TGEN
Tecogen (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten